Spirulina platensis, is an alga rich in phycocyanin (potent antioxidant), is effective in regulating the balance of oxidative stress. The objective of this study is to observe the impact of ingestion of a highly oxidised vegetable oil, by rats of Wistar strain. Finally, we observe the effect of Spirulina used as an antioxidant treatment, on rats having ingested a diet rich in highly oxidised oil. Physiological, biochemical and histological studies have been carried out; the oxidative stress parameters evaluated and a dosing of Cytochrome P450 2E1 was finally carried out. Following the introduction of highly oxidised vegetable oil, rats showed deterioration in their metabolic state, an imbalance in the balance of oxidative stress, an increase in serum concentrations of Cytochrome P450 2E1 and significant hepatic lesions. The administration of a daily dose of Spirulina reduces the deleterious effect of oxidative stress induced by a diet enriched with lipid peroxides.

A randomized, two-way, crossover study was conducted in 15 fasting, healthy, Algerian volunteers to compare the bioavailability of two brands of Valsartan 80 mg coated breakable tablets. The present study aimed to evaluate the intra-subject variability of this active substance in the Algerian population. The test brand was compared to TAREG (Novartis) as the reference product. The study was performed at the bioequivalence center of the national control laboratory for pharmaceuticals products, in joint venture with University Hospital Center Ibn Badis, Constantine, Algeria. The drug was administered with 200 mL of water after a 10 h overnight fasting on two treatment days separated by one week washout period. After dosing, serial blood samples were collected for a period of 24 h. A reliable, simple, and robust liquid chromatography-tandem mass spectro-metric (LC-MS/MS) method has been developed and validated that employs protein precipitation (or denaturation) for the estimation of valsartan in human plasma using losartan as internal standard. The assay was found to be linear over the range of 50-5,000 ng/mL, with a lower limit of quantitation of 50ng/mL. Various pharmacokinetic parameters including AUC0 -t , AUC0 -∞ , C max , T max , and T 1/2 were determined from plasma concentrations of both formulations and found to be in good agreement with reported values. The pharmacokinetical and statistical analysis was conducted with Kinetica 4.4.1. AUC 0-t , AUC 0-∞ and C max were tested for bioequivalence after log-transformation of data. No significant difference was found based on ANOVA; 90% confidence interval ([85.82%, 118.76%] for AUC 0-t [86.09%, 118.83%] for AUC 0-∞ ) of test/reference ratio for these parameters were found within bioequivalence acceptance range of 80-125%. But for the C max , the 90% confidence interval of test/reference ratio wasn't in this acceptance range [90.18%, 131.07%] .The results of PK analysis suggested that the reference and test formulations of valsartan 80 mg coated breakable tablets weren't bioequivalent during fasting state in these healthy algerian volunteers.

A randomized, two-way, crossover study was conducted in 18 fasting, healthy, algerian volunteers to compare the bioavailability of two brands of Omeprazole 20 mg Gastro-Resistant Capsules where MOPRAL (Astra Zeneca) was the reference product. The study was performed at the bioequivalence center of the national control laboratory for pharmaceuticals product. The drug was administered on two treatment days separated by one week washout period. After dosing, serial blood samples were collected for a period of 12 h. A reliable and robust LC-MS/MS (liquid chromatography-tandem mass spectrometry) method has been developed and validated for the estimation of Omeprazole in human plasma. The assay was found to be linear over the range of 5-1,000 ng/mL. The pharmacokinetical and statistical analysis was conducted with Kinetica 4.4.1. AUC 0-t , AUC 0-∞ and C max were tested for bioequivalence. No significant difference was found based on ANOVA; 90% confidence interval ([97.14%-117..85%] for AUC 0-t , [97.17%-117.67%] for AUC 0-∞ ) of test/reference ratio for these parameters were found within bioequivalence acceptance range of 80%-125%. But for the C max , it was not in this acceptance range [73.5%-100.54%]. The results of PK analysis suggested that the reference and test formulations of Omeprazole 20 mg Gastro-Resistant Capsules were not bioequivalent during fasting state in these healthy Algerian volunteers.